REMARKS

This Preliminary Amendment is provided in order to amend the specification to be consistent with Applicant's response to the formalities letter mailed May 27, 2004 wherein a CRF of sequence listings presently added to the specification has been provided to the Patent Office. Sequence listings were identified by Sequence ID number on the CRF and paper copy.

No new matter has been added to the specification by the "Sequence Listing" amendment as the sequences have been previously disclosed in the paper of Clements et al., *Biochem. and Biophys. Res. Comm.*, 284:1189-1193 (2001) noted on page 7, lines 9-15 of the specification.

Date: July 14, 2004

Pfizer Inc. Patent Department MS 8260-1611 Eastern Point Road Groton, CT 06340 (617) 551-3285 Respectfully submitted,

Nicholas I. Slepchuk, Jr. Attorney for Applicant(s) Registration No. 32,174